Stocks and Investing
Stocks and Investing
Thu, November 9, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Vikram Purohit Maintained (ASND) at Hold with Increased Target to $116 on, Nov 9th, 2023
Vikram Purohit of Morgan Stanley, Maintained "Ascendis Pharma A/S" (ASND) at Hold with Increased Target from $113 to $116 on, Nov 9th, 2023.
Vikram has made no other calls on ASND in the last 4 months.
There are 3 other peers that have a rating on ASND. Out of the 3 peers that are also analyzing ASND, 0 agree with Vikram's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Vikram
- Andreas Argyrides of "Wedbush" Reiterated at Buy and Held Target at $192 on, Wednesday, November 8th, 2023
- Li Watsek of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $152 on, Friday, September 15th, 2023
- Derek Archila of "Wells Fargo" Maintained at Buy with Decreased Target to $134 on, Wednesday, September 6th, 2023
Contributing Sources